What genetic mutations are commonly found in Endometrial Cancer

Genetic Mutations in Endometrial Cancer

Great question! Understanding the genetic mutations in endometrial cancer is increasingly important because they help doctors predict how your cancer might behave and which treatments may work best for you.

The Four Major Molecular Subtypes

According to the NCCN Guidelines for Uterine Neoplasms, researchers have identified four clinically significant molecular subtypes of endometrial cancer, each with different genetic mutations and different prognoses:

1. POLE-Mutated Endometrial Cancer

What it is: POLE stands for "DNA polymerase epsilon," an enzyme that helps copy DNA. Mutations in the exonuclease domain (the part that corrects errors) are the key finding here.

Common POLE mutations include:

• P286R and V411L (the most common)
• S297F, A456P, and S459F

What this means clinically:

• These tumors are usually high-grade (more aggressive-looking under the microscope)
• They often have deep myometrial invasion (the cancer has grown deep into the uterine muscle)
• They frequently show LVSI (lymphovascular space invasion—cancer cells in blood vessels)
• Important: Despite these aggressive features, POLE-mutated cancers typically have a good prognosis (better outcomes)

2. MSI-H or dMMR (Mismatch Repair Deficient)

What it is: MSI-H stands for "microsatellite instability-high," and dMMR means "mismatch repair deficient." These refer to problems with the DNA repair system that normally catches and fixes copying errors.

What this means clinically:

• These tumors have an intermediate prognosis (between good and poor)
• They may be associated with Lynch syndrome (a hereditary cancer predisposition)
• Research is ongoing about their sensitivity to chemotherapy
• Genetic counseling is recommended because of the Lynch syndrome connection

3. p53 Aberrant (Mutant p53)

What it is: p53 is called the "guardian of the genome" because it normally stops cancer development. When p53 is mutated or "aberrant," this protective function is lost.

What this means clinically:

• This is the most aggressive subtype with the poorest prognosis
• These cancers typically require multimodality treatment, especially chemotherapy
• They often have copy number-high changes (meaning multiple DNA segments are duplicated or deleted)
• HER2 testing is recommended for all p53 aberrant cancers

4. NSMP (No Specific Molecular Profile)

What it is: Also called "wild-type p53" or "copy number-low," these tumors don't fit into the other three categories.

What this means clinically:

• These have a variable prognosis
• Treatment decisions depend on other clinical factors

---

Other Important Genetic Findings

Lynch Syndrome Connection

According to NCCN Guidelines, about 5% of endometrial cancers are caused by inherited genetic mutations, compared to 95% that are sporadic (random). Lynch syndrome is the most common hereditary cancer syndrome associated with endometrial cancer.

Key points about Lynch syndrome:

• Caused by mutations in mismatch repair (MMR) genes
• Increases lifetime endometrial cancer risk to up to 60%
• Genetic counseling and testing are strongly recommended, especially if you:
  • Were diagnosed before age 50
  • Have a strong family history of endometrial or colorectal cancer
  • Have MSI-H or dMMR status

HER2 Testing

The NCCN Guidelines recommend HER2 immunohistochemistry (IHC) testing for:

• All p53 aberrant carcinomas (regardless of histology)
• All metastatic or recurrent disease

This is important because HER2-positive cancers may respond to targeted therapies like trastuzumab (Herceptin).

Other Mutations to Consider

For metastatic or recurrent endometrial cancer, doctors may also test for:

• NTRK gene fusions (can be treated with targeted therapies)
• RET gene fusions (emerging treatment options)
• Tumor Mutational Burden (TMB) (helps predict immunotherapy response)

---

Why Molecular Testing Matters

According to the NCCN Guidelines, comprehensive molecular profiling is strongly encouraged using:

• FDA-approved assays, OR
• Validated tests performed in CLIA-certified laboratories

This testing helps because:

• Different molecular subtypes may respond to therapy differently
• It guides decisions about whether to escalate or de-escalate treatment
• It identifies patients who might benefit from clinical trials
• It can reveal hereditary cancer syndromes affecting you and your family

---

Questions to Ask Your Oncologist

1. Has my tumor been tested for these molecular mutations (POLE, MSI-H/dMMR, p53)?
2. What is my tumor's molecular subtype, and what does that mean for my prognosis?
3. Do I need genetic counseling or Lynch syndrome testing based on my results?
4. How will my molecular profile affect my treatment recommendations?
5. Are there clinical trials available for my specific molecular subtype?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.